An act to add Section 1374.6 to the Health and Safety Code, and to add Section 10123.62 to the Insurance Code, relating to health care coverage.
Summary
AB 575, the Obesity Prevention Treatment Parity Act, would require most group and individual health care service plan contracts and health insurance policies in California that cover outpatient prescription drugs to include coverage for at least one FDA-approved anti-obesity medication and intensive behavioral therapy for obesity. The mandate would apply to policies and contracts issued, amended, or renewed on or after January 1, 2026, and the required coverage would have to be provided without prior authorization. The bill specifically references GLP-1 receptor agonists as an example of covered anti-obesity medications, but it does not require coverage of every such drug.
The bill also limits how plans and insurers may manage this coverage. While utilization management is still allowed, medical-necessity determinations must be handled the same way they are for other covered conditions, and coverage criteria for anti-obesity medications cannot be more restrictive than the FDA-approved indications. The bill excludes specialized dental-only or vision-only plans and Medicare supplement contracts from its requirements.
Impact
AB 575 would add new coverage mandates to both the Health and Safety Code and the Insurance Code, expanding state insurance law to require obesity treatment coverage in plans and policies that include outpatient prescription drug benefits. It would affect health care service plans regulated by the Department of Managed Health Care and health insurers regulated by the Department of Insurance, while also creating potential enforcement consequences because willful violations by a health care service plan could be treated as a crime under existing law. The bill would not require reimbursement to local agencies or school districts under its stated constitutional findings.
Sentiment
The bill’s stated purpose and framing are strongly supportive of broader access to obesity treatment, emphasizing obesity as a chronic disease, health equity, and the need to reduce stigma and barriers to care. The legislative findings suggest a favorable policy rationale centered on medical consensus, public health costs, and disparities affecting communities of color and low-income Californians. No committee transcript or recorded vote information was provided, and the bill’s last action indicates it was filed with the Chief Clerk pursuant to Joint Rule 56, so there is no direct evidence in the supplied materials of floor or committee opposition or support beyond the bill text itself.
Contention
The main policy tension in the bill is between expanding access to expensive obesity medications and preserving insurer and plan utilization controls. Supporters’ rationale, as reflected in the findings, is that obesity should be treated like other chronic diseases and that patients should not have to meet a severe-obesity threshold before receiving medication coverage. Potential concerns for opponents or cautious stakeholders would likely focus on premium impacts, cost containment, and the scope of mandated coverage for GLP-1 drugs and related therapies. The bill attempts to address some of those concerns by allowing utilization management and by limiting the mandate to at least one FDA-approved medication rather than all such drugs.